DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
Location: France, Provence-Alpes-Côte d'Azur, Marseille
Employees: 1-10
Total raised: $35.2M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | T1D Fund | t1dfund.or... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.05.2023 | Series A | $30.13M | Eli Lilly ... |
| 16.06.2020 | Seed | $5.07M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia... | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital fl... | fiercebiot... |
| 11.05.2023 | Biotech startup DiogenX secures €27.5M to develop therapeuti... | Marseille-based DiogenX, a preclinical-stage biotech company specialising in the development of panc... | siliconcan... |
| 10.05.2023 | DiogenX Raises €27.5M in Series A Financing | DiogenX, a Marsille, France-based biotech company focused on regenerating insulin-producing beta cel... | finsmes.co... |
| 16.06.2020 | DiogenX Raises €4.5M in Seed Financing | DiogenX, a Marseille, France-based preclinical stage biotech company specializing in the development... | finsmes.co... |
| - | DiogenX | “DiogenX is a preclinical stage biotech company committed to a single mission: to discover and devel... | fastfounde... |